Uncategorized

CREATE jumps into CAR T competition with $122M series B

Published

on

CREATE Medicines is working on a clinical-stage pipeline for cancer, while its autoimmune programs are still in preclinical testing.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version